SHERMAN JEFFREY W
SEC CIK 1230482 · EDGAR
BoughtSold
Most active insiders at LRMR, 12 months
| # | Insider | Title | Bought | Sold |
|---|---|---|---|---|
| 1 | Deerfield Mgmt HIF, L.P. | Dir, 10%, * Dir by Deputization | $25.00M | — |
| 2 | Hamilton Thomas Edward | Dir | $666.9K | — |
| 3 | THOMAS FRANK E | Dir | $25.0K | — |
| 4 | SHERMAN JEFFREY W | Dir | $25.0K | — |
| 5 | Shankar Gopi | Chief Development Off | — | — |
| 6 | Clayton Russell | Chief Medical Off | — | — |
| 7 | BEN-MAIMON CAROLE | Pres, CEO, Dir | — | — |
| 8 | Celano Michael | CFO | — | — |
Transactions 10
| X | Filed | Traded | Ticker | Company | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-03-02 | 2026-02-27 | LRMR | Larimar Therapeutics, Inc. | SHERMAN JEFFREY W | Dir | P - Purchase | $5.00 | +5,000 | 5,000 | New | +$25.0K | |
| D | 2025-08-29 | 2025-08-28 | XERS | Xeris Biopharma Holdings, Inc. | SHERMAN JEFFREY W | Dir | M - OptEx | $6.66 | +47.0K | 261.4K | +22% | +$313.3K |
| D | 2025-08-29 | 2025-08-28 | XERS | Xeris Biopharma Holdings, Inc. | SHERMAN JEFFREY W | Dir | S - Sale+OE | $7.92 | -42.2K | 219.2K | -16% | -$334.5K |
| 2025-06-04 | 2025-06-04 | XERS | Xeris Biopharma Holdings, Inc. | SHERMAN JEFFREY W | Dir | A - Grant | $0.00 | +50.0K | 214.4K | +30% | $0 | |
| 2024-06-05 | 2024-06-05 | XERS | Xeris Biopharma Holdings, Inc. | SHERMAN JEFFREY W | Dir | A - Grant | $0.00 | +50.0K | 164.4K | +44% | $0 | |
| 2024-04-11 | 2024-03-15 | XERS | Xeris Biopharma Holdings, Inc. | SHERMAN JEFFREY W | Dir | J - Other | — | +6,502 | 114.4K | +6% | — | |
| I | 2023-11-29 | 2023-11-27 | XERS | Xeris Biopharma Holdings, Inc. | SHERMAN JEFFREY W | Dir | P - Purchase | $1.87 | +5,400 | 5,400 | New | +$10.1K |
| 2023-06-07 | 2023-06-07 | XERS | Xeris Biopharma Holdings, Inc. | SHERMAN JEFFREY W | Dir | A - Grant | $0.00 | +42.5K | 107.9K | +65% | $0 | |
| D | 2022-06-09 | 2022-06-08 | XERS | Xeris Biopharma Holdings, Inc. | SHERMAN JEFFREY W | Dir | A - Grant | $0.00 | +15.0K | 65.4K | +30% | $0 |
| D | 2021-10-05 | 2021-10-05 | XERS | Xeris Biopharma Holdings, Inc. | SHERMAN JEFFREY W | Dir | A - Grant | — | +50.4K | 50.4K | New | — |
Purchase Sale Sale after option exercise All abbreviations